<?xml version='1.0' encoding='utf-8'?>
<document id="31932871"><sentence text="Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors."><entity charOffset="54-63" id="DDI-PubMed.31932871.s1.e0" text="pazopanib" /><entity charOffset="68-77" id="DDI-PubMed.31932871.s1.e1" text="sunitinib" /><pair ddi="false" e1="DDI-PubMed.31932871.s1.e0" e2="DDI-PubMed.31932871.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31932871.s1.e0" e2="DDI-PubMed.31932871.s1.e1" /></sentence><sentence text="Sunitinib and pazopanib, two tyrosine kinase inhibitors (TKI), may be targets of potential pharmacokinetic drug-drug interactions (P-PK-DDIs)"><entity charOffset="0-9" id="DDI-PubMed.31932871.s2.e0" text="Sunitinib" /><entity charOffset="14-23" id="DDI-PubMed.31932871.s2.e1" text="pazopanib" /><entity charOffset="29-37" id="DDI-PubMed.31932871.s2.e2" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31932871.s2.e0" e2="DDI-PubMed.31932871.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31932871.s2.e0" e2="DDI-PubMed.31932871.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31932871.s2.e0" e2="DDI-PubMed.31932871.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31932871.s2.e1" e2="DDI-PubMed.31932871.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31932871.s2.e1" e2="DDI-PubMed.31932871.s2.e2" /></sentence><sentence text=" While strong cytochrome P4503A (CYP3A4) inhibitors or inducers should cause a clinically relevant modification in plasma TKI concentrations, the effect of weak inhibitors is unknown" /><sentence text=" The objective of this study was to evaluate the association between weak P-PK-DDI and clinically relevant toxicity in real life" /><sentence text="" /><sentence text="This was a single-center retrospective study including patients treated with sunitinib or pazopanib for any malignancies, for whom a PK-DDI analysis was performed before starting TKI"><entity charOffset="77-86" id="DDI-PubMed.31932871.s6.e0" text="sunitinib" /><entity charOffset="90-99" id="DDI-PubMed.31932871.s6.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.31932871.s6.e0" e2="DDI-PubMed.31932871.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31932871.s6.e0" e2="DDI-PubMed.31932871.s6.e1" /></sentence><sentence text=" The primary endpoint was the correlation between P-PK-DDIs and a dose decrease after 1 month of treatment" /><sentence text=" The secondary endpoint was the correlation between PK-DDIs and drug withdrawal due to toxicity" /><sentence text="" /><sentence text="Seventy-six patients were assessed" /><sentence text=" A P-PK-DDI with weak CYP3A4 or P-gp inhibition was found in 14 patients" /><sentence text=" In patients with P-PK-DDI or without, the dose was reduced during the first month in 57" /><sentence text="1% and 17" /><sentence text="7% (p = 0" /><sentence text="003) and the drug withdrawn in 42" /><sentence text="8% and 11" /><sentence text="3% (p = 0" /><sentence text="011), respectively" /><sentence text=" In multivariate analysis, a significant correlation was found between P-PK-DDI (CYP3A4 and P-gp inhibitors) and dose reduction, and between drug withdrawal and PK-DDI (CYP3A4 inhibitors)" /><sentence text="" /><sentence text="P-PK-DDI was correlated with dose reduction and drug withdrawal due to toxicity" /><sentence text=" The causality of this relationship warrants to be assessed; therefore, therapeutic drug monitoring is necessary in patients treated with TKI" /><sentence text="" /></document>